chd8  (Bethyl)

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) Schematic of Chd8 protein domains with location of antibody epitopes indicated. The red line corresponds to the location of the 5bp deletion mutation to generate the Chd8 5bpdel/+ mouse line. B) Immunohistochemistry of Chd8 localization in PND2 mouse cortex, DIV14 primary neuron culture and HEK293T cells. Scale bar = 50µm. C) Schematic of endogenous immunoprecipitation approach. D) PCA plot showing peptide spectra variance of PC1 and PC2 in the four IP conditions, dimension reduction was performed on all proteins detected after IP. E) STRING Chd8 PPI network of all proteins considered significant for both Chd8 antibodies by SAINTexpress and DEP. Color of the outside ring indicates the annotated GO term. Inner circle color indicates the level of significance calculated via DEP. Network was made using default settings for a full STRING network indicating both functional and physical protein associations.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Mutagenesis, Immunohistochemistry, Immunoprecipitation, Functional Assay

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) MCL clustering of STRING Chd8 protein-protein network with all proteins identified by either Chd8 antibody via either SAINTexpress or DEP at a P-value < 0.05 significance cutoff. MCL clustering was performed with the granularity parameter set to 6. Color of the outside ring indicates the annotated GO term. Inner circle color indicates if the protein was included in the more stringent 222 Chd8 interacting protein set. Network was made using default settings for a physical STRING network indicating the proteins are part of a physical complex. B) Western blotting of Co-IP validation of Chd8 protein interactions. Co-IP was performed using either the C-terminus or N- terminus Chd8 antibody, indicated by the top labels. The antibody used for western blotting is indicated to the right and the molecular weight (kDa) of the band to the left. C) Colocalization validation of protein interactions. D) Schematic of Proximity Ligation Assay (PLA) approach. PLA visualizes protein interactions via fluorescent signal amplification when targets are in close molecular proximity. E) PLA validation of Chd8 protein interactions. Nuclei were stained blue with Hoechst, with red dots indicating locations where the two target proteins are interacting. F-G) Western blotting of Chd8 Co-IP after RNase treatment. +/- indicates the presence or absence of RNase, respectively. The top labels indicate the antibody used for Co-IP. F) Co-IP of Rbm8a. G) Co-IP of Paf1.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Western Blot, Co-Immunoprecipitation Assay, Biomarker Discovery, Molecular Weight, Proximity Ligation Assay, Amplification, Staining

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A. Schematic of the protein construct used for TurboID. B) Epifluorescence images validation of localization and biotinylation activity of CHD8-Turbo in HEK293T cells. Protein localization was stained by anti-HA antibodies and biotinylation activity was stained by fluorescently conjugated Neutravidin. C) STRING PPI network of the CHD8-Turbo fusion protein in HEK293T cells. Color of the outside ring indicates the annotated GO term. Network was made using default settings for a full STRING network indicating both functional and physical protein associations. D) Heatmap of GO term enrichment across multiple Chd8 pulldown conditions. The number of proteins included in each condition is indicated in parentheses.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Construct, Biomarker Discovery, Activity Assay, Staining, Functional Assay

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) Schematic of PND2 forebrain RIP-seq method. B) Quantification of RNA that was isolated from Chd8 Co-IP from PND2 mouse forebrain. C) Quantification of RNA that was isolated from Chd8 Co-IP after DNase and RNase treatment. D) PCA plot showing transcriptional variance of PC1 and PC2 in the four IP conditions used for RIP-seq, dimension reduction was performed on the top 500 variable genes. Antibodies used for IP conditions are indicated by color. E) Volcano plot showing log fold change and significance of mRNA enriched after IP via the C-terminus antibody vs IgG control. Significant enrichment in C-terminus vs IgG is shown in red (P value < 0.05) with highly significant enrichment (FDR < 0.1) shown in dark red. 263 genes showed significant enrichment in the C-terminus RIP-seq vs IgG. F) Density plots showing the frequency of gene overlaps from permutation tests comparing the top 1000 C-terminus RIP-seq enriched genes and Chd8-bound genes from, the top 1000 Chd8 TaDa-seq (Wade 2021) genes (P = 0.0874), the top 1000 Chd8 CHIP- seq (Platt 2017) genes (P = 0.0232), and the 856 Chd8 CHIP-seq (Gompers 2016) genes (P = 0.0784). Observed intersections in shown in red. G) Gene ontology enrichment of genes significantly (P < 0.05) enriched in C-terminus RIP-seq. Strength and significance of enrichment, as well as number of DEGs present in gene set is indicated. Gene sets with DEGs highlighted in panel H are colored. H) Heatmap showing the z-scale normalized counts of DEGs present in indicated gene sets across C-terminus and IgG IP samples. Color to the left indicates the enriched gene set.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Isolation, Co-Immunoprecipitation Assay, Control, ChIP-sequencing

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) Volcano plot of individual protein pulldown in Chd8 5bpdel/+ and wildtype mice including proteins identified by either Chd8 antibody via SAINTexpress or DEP at a P-value < 0.05 cutoff. Green and blue proteins are significantly differential for Chd8 5bpdel/+ or Chd8 +/+ forebrain at a significance of P- value < 0.05. B) GO terms enriched in proteins significantly increased in Chd8 5bpdel/+ or Chd8 +/+ forebrain. Set overlap indicates the number of significantly increased proteins and total detected indicates the total number from all proteins analyzed. C) Volcano plot of individual protein pulldown in Chd8 5bpdel/+ and wildtype mice. Color indicates the annotated GO term. D) The observed average fold change of multiple GO terms. SEM and p-values calculated by permutation test. Sample size for each permutation corresponds to the number of annotated proteins for each GO term. E) Heatmap comparing Odd Ratio values across Chd8 antibody and mouse genotype for all proteins associated with mRNA Splicing, via Spliceosome (GO:0000398).

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques:

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) Schematic of Chd8 protein domains with location of antibody epitopes indicated. The red line corresponds to the location of the 5bp deletion mutation to generate the Chd8 5bpdel/+ mouse line. B) Immunohistochemistry of Chd8 localization in PND2 mouse cortex, DIV14 primary neuron culture and HEK293T cells. Scale bar = 50µm. C) Schematic of endogenous immunoprecipitation approach. D) PCA plot showing peptide spectra variance of PC1 and PC2 in the four IP conditions, dimension reduction was performed on all proteins detected after IP. E) STRING Chd8 PPI network of all proteins considered significant for both Chd8 antibodies by SAINTexpress and DEP. Color of the outside ring indicates the annotated GO term. Inner circle color indicates the level of significance calculated via DEP. Network was made using default settings for a full STRING network indicating both functional and physical protein associations.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Mutagenesis, Immunohistochemistry, Immunoprecipitation, Functional Assay

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) MCL clustering of STRING Chd8 protein-protein network with all proteins identified by either Chd8 antibody via either SAINTexpress or DEP at a P-value < 0.05 significance cutoff. MCL clustering was performed with the granularity parameter set to 6. Color of the outside ring indicates the annotated GO term. Inner circle color indicates if the protein was included in the more stringent 222 Chd8 interacting protein set. Network was made using default settings for a physical STRING network indicating the proteins are part of a physical complex. B) Western blotting of Co-IP validation of Chd8 protein interactions. Co-IP was performed using either the C-terminus or N- terminus Chd8 antibody, indicated by the top labels. The antibody used for western blotting is indicated to the right and the molecular weight (kDa) of the band to the left. C) Colocalization validation of protein interactions. D) Schematic of Proximity Ligation Assay (PLA) approach. PLA visualizes protein interactions via fluorescent signal amplification when targets are in close molecular proximity. E) PLA validation of Chd8 protein interactions. Nuclei were stained blue with Hoechst, with red dots indicating locations where the two target proteins are interacting. F-G) Western blotting of Chd8 Co-IP after RNase treatment. +/- indicates the presence or absence of RNase, respectively. The top labels indicate the antibody used for Co-IP. F) Co-IP of Rbm8a. G) Co-IP of Paf1.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Western Blot, Co-Immunoprecipitation Assay, Biomarker Discovery, Molecular Weight, Proximity Ligation Assay, Amplification, Staining

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A. Schematic of the protein construct used for TurboID. B) Epifluorescence images validation of localization and biotinylation activity of CHD8-Turbo in HEK293T cells. Protein localization was stained by anti-HA antibodies and biotinylation activity was stained by fluorescently conjugated Neutravidin. C) STRING PPI network of the CHD8-Turbo fusion protein in HEK293T cells. Color of the outside ring indicates the annotated GO term. Network was made using default settings for a full STRING network indicating both functional and physical protein associations. D) Heatmap of GO term enrichment across multiple Chd8 pulldown conditions. The number of proteins included in each condition is indicated in parentheses.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Construct, Biomarker Discovery, Activity Assay, Staining, Functional Assay

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) Schematic of PND2 forebrain RIP-seq method. B) Quantification of RNA that was isolated from Chd8 Co-IP from PND2 mouse forebrain. C) Quantification of RNA that was isolated from Chd8 Co-IP after DNase and RNase treatment. D) PCA plot showing transcriptional variance of PC1 and PC2 in the four IP conditions used for RIP-seq, dimension reduction was performed on the top 500 variable genes. Antibodies used for IP conditions are indicated by color. E) Volcano plot showing log fold change and significance of mRNA enriched after IP via the C-terminus antibody vs IgG control. Significant enrichment in C-terminus vs IgG is shown in red (P value < 0.05) with highly significant enrichment (FDR < 0.1) shown in dark red. 263 genes showed significant enrichment in the C-terminus RIP-seq vs IgG. F) Density plots showing the frequency of gene overlaps from permutation tests comparing the top 1000 C-terminus RIP-seq enriched genes and Chd8-bound genes from, the top 1000 Chd8 TaDa-seq (Wade 2021) genes (P = 0.0874), the top 1000 Chd8 CHIP- seq (Platt 2017) genes (P = 0.0232), and the 856 Chd8 CHIP-seq (Gompers 2016) genes (P = 0.0784). Observed intersections in shown in red. G) Gene ontology enrichment of genes significantly (P < 0.05) enriched in C-terminus RIP-seq. Strength and significance of enrichment, as well as number of DEGs present in gene set is indicated. Gene sets with DEGs highlighted in panel H are colored. H) Heatmap showing the z-scale normalized counts of DEGs present in indicated gene sets across C-terminus and IgG IP samples. Color to the left indicates the enriched gene set.

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques: Isolation, Co-Immunoprecipitation Assay, Control, ChIP-sequencing

Journal: bioRxiv

Article Title: Molecular interactions of Chd8 in mouse brain highlights a role in chromatin-associated RNA processing

doi: 10.64898/2025.12.11.693549

Figure Lengend Snippet: A) Volcano plot of individual protein pulldown in Chd8 5bpdel/+ and wildtype mice including proteins identified by either Chd8 antibody via SAINTexpress or DEP at a P-value < 0.05 cutoff. Green and blue proteins are significantly differential for Chd8 5bpdel/+ or Chd8 +/+ forebrain at a significance of P- value < 0.05. B) GO terms enriched in proteins significantly increased in Chd8 5bpdel/+ or Chd8 +/+ forebrain. Set overlap indicates the number of significantly increased proteins and total detected indicates the total number from all proteins analyzed. C) Volcano plot of individual protein pulldown in Chd8 5bpdel/+ and wildtype mice. Color indicates the annotated GO term. D) The observed average fold change of multiple GO terms. SEM and p-values calculated by permutation test. Sample size for each permutation corresponds to the number of annotated proteins for each GO term. E) Heatmap comparing Odd Ratio values across Chd8 antibody and mouse genotype for all proteins associated with mRNA Splicing, via Spliceosome (GO:0000398).

Article Snippet: CHD8 immunoprecipitation was performed with antibodies targeted to either the C- terminal (Bethyl, A301-225A) or N-terminal (Bethyl, A301-224A) end of CHD8.

Techniques:

Journal: The EMBO Journal

Article Title: CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer

doi: 10.1038/s44318-025-00447-8

Figure Lengend Snippet: ( A ) Rapid Immunoprecipitation mass spectrometry of endogenous proteins (RIME) was performed on a range of TNBC samples and primary mouse B-cells, using BCL11A as a bait protein. Detailed results from the mass spectrometry analysis including protein accession number, gene description, mascot score, coverage, and unique peptides have been included in Dataset EV – . For cumulative Mascot score word cloud analysis (bottom panels), we first subtracted proteins identified from the BCL11A IP mass spec that were also present in the IgG isotype control IP mass spec, thereby removing any non-specific proteins. Subsequently, proteins with a minimum of one unique peptide were included and the cumulative mascot score was calculated. The word cloud represents each protein and the size representative to the mascot score. This analysis was performed on two independent B-cell runs (right word cloud) and seven independent TNBC cell line or PDX tissue runs (left word cloud). This identified CHD8 as a major interacting partner in TNBC samples but not B cells, with CHD8 being the only interaction partner identified in all TNBC samples. ( B ) 4T1 cells were transfected with plasmids encoding either Chd8 shRNA or gRNA sequences and were subsequently used in 3D colony assays or xenografted into mice for tumour growth assays ( n = 3). An ordinary one-way ANOVA with a Dunnett multiple comparison correction was used. Means of each test condition were compared to the mean of the control condition. P values reported are * p < 0.05; ** p < 0.01; *** p < 0.001 and **** p < 0.0001. shRNA-mediated knockdown of Chd8 in mouse TNBC 4T1 cells leads to a reduction in tumour growth in both 3D colony assays (left panel) and xenograft transplantation assays (middle panel), CRISPR-mediated knockout of Chd8 produces similar results (right panel) demonstrating that CHD8 also plays a role in TNBC ( n = 4). Error bars on the box and whisker denote the minimum and maximum datapoints, the box bounds are the upper and lower quartile values and the line in the middle of the box if is the median value. An ordinary one-way ANOVA with a Dunnett multiple comparison correction was used for statistical analysis of the xenograft plots. Means of each knockdown condition were compared to the mean of the control condition. * p < 0.05; * p < 0.01; *** p < 0.001 and **** p < 0.0001. The Western Blot in this figure panel is also shown in Appendix Fig. S . ( C ) Western blot analysis of BCL11A and CHD8 was performed in patient-derived xenografts derived from TNBC or luminal breast tumours. This identified selective upregulation of both proteins in TNBC tumours but not luminal breast cancer tumours. Further qPCR analysis showed amplification of BCL11A RNA in TNBC tumours ( n = 14) versus luminal tumours ( n = 9), whereas CHD8 is unaltered at the RNA level. Error bars on the box and whisker denote the minimum and maximum datapoints, the box bounds are the upper and lower quartile values and the line in the middle of the box if is the median value. ( D ) Western blot analysis of BCL11A and CHD8 was performed using tumours derived from a Brca1f/f p53+/− Blg-Cre mouse model, in which mice spontaneously form TNBC tumours. This showed upregulation of both proteins and upregulation of BCL11A only at the RNA level ( n = 6). Controls in this experiment were mammary gland preparations from C57BL/6 mice ( n = 3). Error bars on the box and whisker denote the minimum and maximum datapoints, the box bounds are the upper and lower quartile values and the line in the middle of the box if is the median value. ( E ) Knockdown of Bcl11a using shRNA in 4T1 cells showed a reduction in the levels of BCL11A and CHD8 protein, with a corresponding reduction in Bcl11a RNA but not Chd8 RNA ( n = 3). An ordinary one-way ANOVA with a Dunnett multiple comparison correction was used for statistical analysis of these plots. Means of each knockdown condition were compared to the mean of the control condition. * p < 0.05; * p < 0.01; *** p < 0.001 and **** p < 0.0001. The Western Blot in this figure panel is also shown in Appendix Fig. S . .

Article Snippet: Anti-CHD8 antibody , Bethyl , A301-225A-M.

Techniques: Immunoprecipitation, Mass Spectrometry, Control, Transfection, shRNA, Comparison, Knockdown, Transplantation Assay, CRISPR, Knock-Out, Whisker Assay, Western Blot, Derivative Assay, Amplification

Journal: The EMBO Journal

Article Title: CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer

doi: 10.1038/s44318-025-00447-8

Figure Lengend Snippet: ( A ) To further explore the role of BCL11A and CHD8 in TNBC, multi-OMICS analysis of 4T1 cells transfected with either control shRNA, Bcl11a-targeting shRNA or Chd8-targeting shRNA was performed. Cells were submitted for bulk RNAseq; ChIPseq, to investigate genomic binding of BCL11A and CHD8; and ATACseq, to investigate modulation of chromatic accessibility. ( B ) Bulk RNAseq identified a number of protein-specific gene targets, but also identified a large subset of overlapping target genes. The expression of overlapping gene targets appeared to be affected in similar directions and magnitudes by either Bcl11a or Chd8 knockdown. ( C ) Heat map of the top 30 up- and down-regulated genes from the overlapping gene set. This set of genes is derived from panel B and uses the same scale bar. ( D ) Transcription start site (TSS) heat maps showing the genomic binding behaviour of BCL11A (left panels) and CHD8 (right panels) in control shRNA (top panels), Bcl11a shRNA (middle panels) and Chd8 shRNA (bottom panels) cell lines. Knockdown of either Bcl11a or Chd8 results in an overall reduction of genomic binding for both proteins around the TSS. ( E ) Manual inspection of ChIP-seq data confirms co-dependency of BCL11A and CHD8 for binding to promoter regions. Knockdown of either Bcl11a (red peaks) or Chd8 (blue peaks) results in reduced genomic binding versus control (grey peaks). ATACseq analysis shows that knockdown of Chd8, but not Bcl11a, reduces chromatin accessibility at gene target promoter regions.

Article Snippet: Anti-CHD8 antibody , Bethyl , A301-225A-M.

Techniques: Biomarker Discovery, Transfection, Control, shRNA, Binding Assay, Expressing, Knockdown, Derivative Assay, ChIP-sequencing

Journal: The EMBO Journal

Article Title: CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer

doi: 10.1038/s44318-025-00447-8

Figure Lengend Snippet: ( A ) Western blot analysis of BCL11A and CHD8 was performed on samples from co-immunoprecipitation (Co-IP) experiments. BCL11A and CHD8 were independently immunoprecipitated in human TNBC cells (MDA231), mouse TNBC cells (4T1) patient-derived xenografts (PDX) and wild-type (C57BL/6) mouse spleen. Western Blots validated that BCL11A and CHD8 interact in the TNBC and PDX samples, but not in spleen sampes. ( B ) Western Blot analysis of BCL11A and other members of the CHD family using CoIP samples from panel A. Further analysis showed high specificity of the BCL11A-CHD8 interaction, with no interaction observed between BCL11A and other members of the CHD family. ( C ) To confirm direct interaction of BCL11A and CHD8, recombinant full-length human versions of BCL11A and CHD8 were expressed and purified from Expi293F cells. Cells were lysed and proteins purified via the StrepTag using StrepTactin XT 4-Flow resin. ( D ) Purity and quality of recombinant proteins was assessed by SDS-PAGE and Western Blotting, showing a high purity and mono-dispersity of proteins. ( E ) A surface plasmon resonance (SPR) assay was constructed to confirm direct interaction of BCL11A and CHD8. In this assay, one partner (CHD8) was attached to the surface of an SPR chip, while the other partner (BCL11A) was injected in increasing concentrations. A reference flow cell containing an unrelated protein (BSA) was used as a binding control. Protein binding to the SPR surface causes a change in resonance angle, which can be used to detect protein interactions. ( F ) SPR using recombinant purified proteins confirms a direct interaction between BCL11A and CHD8. A concentration-dependent increase in binding responses was observed upon injection of BCL11A, with slow association and dissociation rates observed. Responses at the end of the sample injection (600 s) were used to estimate the steady-state affinity of the interaction, which was measured at 870 nM (50% Rmax). ( G ) A second SPR assay was constructed, whereby either full-length CHD8 or BCL11A was immobilised to the chip surface. Truncated BCL11A or CHD8 proteins were then injected in series into the flow cell containing their interaction partner (i.e. BCL11A vs CHD8 fragments, CHD8 versus BCL11A fragments). This identified BCL11A 601-835 and CHD8 450-950 as the most likely interface between BCL11A and CHD8. The schematic in panel C was generated using BioRender. .

Article Snippet: Anti-CHD8 antibody , Bethyl , A301-225A-M.

Techniques: Western Blot, Immunoprecipitation, Co-Immunoprecipitation Assay, Derivative Assay, Recombinant, Purification, SDS Page, SPR Assay, Construct, Injection, Binding Assay, Control, Protein Binding, Concentration Assay, Generated

Journal: The EMBO Journal

Article Title: CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer

doi: 10.1038/s44318-025-00447-8

Figure Lengend Snippet: ( A ) GLIDE-based virtual screening using three diverse fragment libraries was performed using PDB structure 6ki6. The top 10% of hits were re-scored and manually inspected, with the best 8 hits purchased for screening. Hits located in the zinc finger 6 region were prioritised due to higher uniqueness in this region compared to BCL11B. ( B ) SPR screening for validation of in silico hits. BCL11A was immobilised to an SPR sensor surface, with each fragment injected at a single high concentration (400 μM). 6 out of the 8 purchased fragments were validated as BCL11A binders. ( C ) Further assessment of validated binders was then performed in a concentration series. Fragments were then injected in a 1:3 serial dilution series to confirm binding and to generate kinetics and affinity data using an SPR chip comprising separate flow cells with either BCL11A or BCL11B immobilised. An example of the concentration series data for fragment 8 is shown for BCL11A and BCL11B binding. All fragments were shown to also bind the homologous BCL11B. ( D ) An SPR assay was constructed to investigate the ability of fragment hits to prevent BCL11A-CHD8 complex formation. Full-length recombinant CHD8 was immobilised to the chip surface, with subsequent injection of BCL11A alone or of BCL11A that had been pre-incubated with 400 μM of each fragment. Inhibition of the complex was determined through a reduction in binding response of BCL11A binding to the chip surface. ( E ) All of the fragments tested prevented BCL11A-CHD8 complex formation with varying efficiencies, indicated by a reduction of BCL11A binding to the CHD8-coated surface. ( F ) Percentage inhibition of BCL11A binding to the chip surface is summarised. Responses are normalised to the BCL11A binding response. .

Article Snippet: Anti-CHD8 antibody , Bethyl , A301-225A-M.

Techniques: Biomarker Discovery, In Silico, Injection, Concentration Assay, Serial Dilution, Binding Assay, SPR Assay, Construct, Recombinant, Incubation, Inhibition

Journal: The EMBO Journal

Article Title: CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer

doi: 10.1038/s44318-025-00447-8

Figure Lengend Snippet: ( A ) To assess the effect of putative BCL11A-CHD8 interaction inhibitors, 4T1, MCF-7 and MDA-MB-231 cells were grown in 3D and treated with inhibitors across 6 days. Cells were imaged at day 0, 3 and 6 for analysis of colony formation. ( B ) Fold change in average 4T1 colony size relative to day 0 size upon treatment of fragments at 200 μM across 6 days of treatment, fitted with simple linear regression identifying that the slopes of fold change in average colony size over time differ globally within 4T1s ( n = 3 passages, F = 3.999, p = 0.025) (left panel). 3D colony assay images visualising the phenotypic changes in 4T1 colony size following 6 days of treatment with 3 selected binders. The scale bar represents 2000um (right panel). ( C ) Co-Immunoprecipitation (CoIP) experiments in which BCL11A and CHD8 were independently immunoprecipitated from 4T1 cells treated with 1% DMSO (vehicle control) or 400 μM of Fragment 1, Fragment 3 or Fragment 5. Anti-BCL11A Western Blots demonstrate that 4T1 treatment has no effect on the levels of BCL11A (input) or in the recognition of BCL11A by an anti-BCL11A antibody (left panels). Conversely, anti-BCL11A Western Blots on CHD8 IP samples (right panels) demonstrates an interaction between CHD8 and BCL11A in the DMSO control, but not in the fragment treatment conditions, suggesting inhibition of the BCL11A-CHD8 interaction by these fragments in a cell-based format. ( D ) Percentage of 4T1 cells in G1, S and G2/M phase following treatment of fragments 1, 3 and 5 at 200 μM for 24 h, determined by flow cytometry. Data presented as median and range ( n = 3 passages), G1 analysed by Kruskal–Wallis test, G2/M and S phase analysed by two-way ANOVA with post-hoc Dunnett’s test identifying a significant difference between treatment with DMSO and Fragment 3 ( p = 0.0294). ( E ) Fold change in average colony size relative to day 0 size comparing human cell lines MCF-7 and MDA-MB-231 upon treatment of fragments 1, 3 and 5 at 200 μM. 3D colony assay images visualising the phenotypic changes in MCF-7 and MDA-MB-231 colony size. The scale bars represent 1000 μm (left panel) Fitted simple linear regressions to fold change in average colony size over time identifies global differences in MDA-MB-231 cells ( n = 3 passages, F = 3.727, p = 0.0226), with no global difference in the slope ( n = 3, F = 0.5817, p = 0.6319) or intercept ( n = 3 passages, F = 0.5734, p = 0.6368) in MCF-7 cells (right panel). .

Article Snippet: Anti-CHD8 antibody , Bethyl , A301-225A-M.

Techniques: Colony Assay, Immunoprecipitation, Control, Western Blot, Inhibition, Flow Cytometry

Journal: Cellular & molecular biology letters

Article Title: Genetic and epigenetic regulation of Treg cell fitness by autism-related chromatin remodeler CHD8.

doi: 10.1186/s11658-025-00711-z

Figure Lengend Snippet: Fig. 1 CHD8 deficiency causes effector T cell-mediated inflammatory disorders. A–C WT and Chd8−/− mice were sacrificed at around 4–5 weeks old. Photos of mice A, spleens B, and their weights (right) are shown. Scale bars equal 1 cm or 2 cm, as indicated. WT: three males + two females; Chd8−/−: two males + two females. Mouse tissues, as indicated, were processed for H&E staining. Representative images are shown (C). The magnified views of skin and lung are also shown on the right of the original images, with red arrows pointing to the infiltrating leukocytes (scale bars equal 100 µm or 200 µm, as indicated). D–E Freshly isolated splenocytes were stained for CD4, CD8, CD62L, and CD44, followed by FACS analysis. Representative dot plots of CD62L and CD44 staining gated on CD4+ (D) or CD8+ (E) cells are shown (left). The percentages of CD44+ cells are shown in bar graphs (right). F Splenocytes were stimulated with PMA plus ionomycin for 5 h, with BD GolgiPlug™ added during the last 2 h. The cells were collected for surface staining of CD4 and CD8 and intracellular cytokine staining for IFN-γ, IL-4, IL-13, and/or IL-17, gated on CD4+ or CD8+cells, as indicated. Representative dot plots (upper) and percentages of cytokine positive CD4+ or CD8+ cells in bar graphs (lower) are shown. Results in bar graphs (D–F) represent mean plus standard deviation (SD) (WT: five males + five females; Chd8−/−: three males + five females). *P < 0.05, **P < 0.01 versus WT control group

Article Snippet: Chromatin was immunoprecipitated by incubating soluble chromatin with 1.5 μg of CHD8 antibody (Bethyl Laboratories, no. A301–224) or 1.5 μg of immunoglobulin G (IgG) antibody (Abcam, ab37355) at 4 °C overnight.

Techniques: Staining, Isolation, Standard Deviation, Control

Journal: Cellular & molecular biology letters

Article Title: Genetic and epigenetic regulation of Treg cell fitness by autism-related chromatin remodeler CHD8.

doi: 10.1186/s11658-025-00711-z

Figure Lengend Snippet: Fig. 4 CHD8 deficiency alters global gene expression. Splenic CD4+ T cells were isolated from WT and Chd8−/− mice (WT: one male + one female; Chd8−/−: one male + one female) by AutoMACS. YFP+ cells were then sorted by FACS and analyzed for gene expression profiles by RNA-Seq. A Heatmap of differentially expressed genes between WT and Chd8−/− Tregs. B Representative upregulated hallmark pathways in Chd8−/− Tregs. C Representative GSEA enrichment plots of upregulated pathways in Chd8−/− Tregs. D Volcano plot of differentially expressed genes between WT and Chd8−/− Tregs. Log2FC cutoff: 1.0; FDR < 0.05. E Fold changes (Chd8−/− versus WT) of representative genes in mTORC1, p53, and ROS signaling pathways

Article Snippet: Chromatin was immunoprecipitated by incubating soluble chromatin with 1.5 μg of CHD8 antibody (Bethyl Laboratories, no. A301–224) or 1.5 μg of immunoglobulin G (IgG) antibody (Abcam, ab37355) at 4 °C overnight.

Techniques: Gene Expression, Isolation, RNA Sequencing, Protein-Protein interactions

Journal: Cellular & molecular biology letters

Article Title: Genetic and epigenetic regulation of Treg cell fitness by autism-related chromatin remodeler CHD8.

doi: 10.1186/s11658-025-00711-z

Figure Lengend Snippet: Fig. 5 CHD8 deficiency leads to chromatin remodeling. Splenic CD4+ T cells were isolated from WT and Chd8−/− mice by AutoMACS. YFP+ cells were then sorted by FACS and analyzed by ATAC-seq and CHIP-seq. A Heatmap of ATAC-seq peaks in WT and Chd8−/− Tregs showing ± 1.5 kb around the ATAC-seq peak center. Results are from one WT male mouse, one Chd8−/− male mouse, and one Chd8−/− female mouse. Cutoff: Log2FC = 0.4. B Genes with altered ATAC-seq peaks in Chd8−/− versus WT cells were analyzed for enrichment in hallmark pathways. Upregulated hallmark pathways and leading-edge genes are shown. Note: no downregulated hallmark pathways were found. C Heatmap of anti-CHD8 CHIP-seq peaks compared with IgG control in Tregs. Results are from one WT male mouse and one WT female mouse. D GSEA enrichment plot of representative pathway of CHD8 binding genes. E Heatmap of ATAC up and ATAC down peaks at CHD8 binding sites in Chd8−/− Tregs. F Heatmap of ATAC up and ATAC down peaks at non-CHD8 binding sites in Chd8−/− Tregs

Article Snippet: Chromatin was immunoprecipitated by incubating soluble chromatin with 1.5 μg of CHD8 antibody (Bethyl Laboratories, no. A301–224) or 1.5 μg of immunoglobulin G (IgG) antibody (Abcam, ab37355) at 4 °C overnight.

Techniques: Isolation, ChIP-sequencing, Control, Binding Assay

Journal: Cellular & molecular biology letters

Article Title: Genetic and epigenetic regulation of Treg cell fitness by autism-related chromatin remodeler CHD8.

doi: 10.1186/s11658-025-00711-z

Figure Lengend Snippet: Fig. 6 Identification of CHD8 target genes whose expression is regulated by CHD8 direct binding-mediated chromatin remodeling. A Overlapping between genes bound by CHD8 and genes upregulated or downregulated in Chd8−/− cells identified through RNA-seq. RNA-seq Cutoff: Log2FC = 0.7. B Enriched pathways of CHD8 direct targets revealed by overlapping CHIP-seq data with RNA-seq data. Gene set enrichment was carried out by using Enrichr. C Heatmaps of RNA-seq, CHIP-seq, and ATAC-seq of CHD8 direct targets that may contribute to Chd8−/− Treg phenotypes. D ATAC-seq and anti-CHD8 CHIP-seq tracks of Cdkn1a, Bhlhe40, and Perp in WT and/or Chd8−/− Tregs

Article Snippet: Chromatin was immunoprecipitated by incubating soluble chromatin with 1.5 μg of CHD8 antibody (Bethyl Laboratories, no. A301–224) or 1.5 μg of immunoglobulin G (IgG) antibody (Abcam, ab37355) at 4 °C overnight.

Techniques: Expressing, Binding Assay, RNA Sequencing, ChIP-sequencing